OncoTherapy Science (TSE:4564) FCF Yield %: -11.76 (As of Jul. 07, 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.04
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science FCF Yield %?

OncoTherapy Science TSE:4564 +5.00% 50 FCF Yield % is -11.76 as of Jul. 07, 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.04 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,408 Biotechnology companies, OncoTherapy Science ranks worse than 56.89% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, OncoTherapy Science's Trailing 12-Month Free Cash Flow is 円-985.0 Mil, and Market Cap is 円8,371.5 Mil. Therefore, OncoTherapy Science's FCF Yield % for today is -11.76%.

The historical rank and industry rank for OncoTherapy Science's FCF Yield % or its related term are showing as below:

TSE:4564' s FCF Yield % Range Over the Past 10 Years
Min: -38.56   Med: -14.19   Max: -6.78
Current: -11.76


During the past 13 years, the highest FCF Yield % of OncoTherapy Science was -6.78%. The lowest was -38.56%. And the median was -14.19%.

TSE:4564's FCF Yield % is ranked worse than
56.89% of 1408 companies
in the Biotechnology industry
Industry Median: -9.305 vs TSE:4564: -11.76

OncoTherapy Science's FCF Margin % for the quarter that ended in Mar. 2026 was -105.92%.


OncoTherapy Science FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


OncoTherapy Science FCF Yield % Related Terms


OncoTherapy Science FCF Yield % Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science FCF Yield % Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.03 -8.84 -26.93 -10.72 -12.23

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.23 -11.21 -6.21 -13.31 -9.90

TSE:4564 vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, OncoTherapy Science's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's FCF Yield % distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's FCF Yield % falls into.


TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

OncoTherapy Science's FCF Yield % for the fiscal year that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-984.967 / 8056.524
=-12.23%

OncoTherapy Science's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-398.929 * 2 / 8056.524
=-9.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -11.76 mean?
OncoTherapy Science (TSE:4564) has a FCF Yield % of -11.76 as of Jul. 07, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #801 out of 1408 companies in the Biotechnology industry, placing it in the top 56.9%.
Is OncoTherapy Science's FCF Yield % too high?
OncoTherapy Science's current FCF Yield % is -11.76. Based on the distribution chart, OncoTherapy Science ranks #801 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #801 out of 1408 companies for FCF Yield %. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current FCF Yield % is -11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.04, compared to a current price of 円21.00 — trading 23.2% above its estimated fair value. The current FCF Yield % is -11.76. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current FCF Yield % is -11.76 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.2% above its estimated GF Value™ of 円17.04. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • FCF Yield %: -11.76
  • GF Value™: 円17.04 vs. price of 円21.00 (23.2% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.04
GF Value